TY - JOUR
T1 - Putting participants and study partners FIRST when clinical trials end early
AU - the Participant FIRST Work Group
AU - Largent, Emily A.
AU - Walter, Sarah
AU - Childs, Nancy
AU - Dacks, Penny A.
AU - Dodge, Shana
AU - Florian, Hana
AU - Jackson, Jonathan
AU - Llibre Guerra, Jorge J.
AU - Iturriaga, Erin
AU - Miller, David S.
AU - Moreno, Monica
AU - Nosheny, Rachel L.
AU - Obisesan, Thomas O.
AU - Portacolone, Elena
AU - Siddiqi, Bernadette
AU - Silverberg, Nina
AU - Warren, Rueben C.
AU - Welsh-Bohmer, Kathleen A.
AU - Edelmayer, Rebecca M.
N1 - Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2022/12
Y1 - 2022/12
N2 - Between 2018 and 2019, multiple clinical trials ended earlier than planned, resulting in calls to improve communication with and support for participants and their study partners (“dyads”). The multidisciplinary Participant Follow-Up Improvement in Research Studies and Trials (Participant FIRST) Work Group met throughout 2021. Its goals were to identify best practices for communicating with and supporting dyads affected by early trial stoppage. The Participant FIRST Work Group identified 17 key recommendations spanning the pre-trial, mid-trial, and post-trial periods. These focus on prospectively allocating sufficient resources for orderly closeout; developing dyad-centered communication plans; helping dyads build and maintain support networks; and, if a trial stops, informing dyads rapidly. Participants and study partners invest time, effort, and hope in their research participation. The research community should take intentional steps toward better communicating with and supporting participants when clinical trials end early. The Participant FIRST recommendations are a practical guide for embarking on that journey.
AB - Between 2018 and 2019, multiple clinical trials ended earlier than planned, resulting in calls to improve communication with and support for participants and their study partners (“dyads”). The multidisciplinary Participant Follow-Up Improvement in Research Studies and Trials (Participant FIRST) Work Group met throughout 2021. Its goals were to identify best practices for communicating with and supporting dyads affected by early trial stoppage. The Participant FIRST Work Group identified 17 key recommendations spanning the pre-trial, mid-trial, and post-trial periods. These focus on prospectively allocating sufficient resources for orderly closeout; developing dyad-centered communication plans; helping dyads build and maintain support networks; and, if a trial stops, informing dyads rapidly. Participants and study partners invest time, effort, and hope in their research participation. The research community should take intentional steps toward better communicating with and supporting participants when clinical trials end early. The Participant FIRST recommendations are a practical guide for embarking on that journey.
UR - https://www.scopus.com/pages/publications/85135346480
U2 - 10.1002/alz.12732
DO - 10.1002/alz.12732
M3 - Article
C2 - 35917209
AN - SCOPUS:85135346480
SN - 1552-5260
VL - 18
SP - 2736
EP - 2746
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 12
ER -